Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.

Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabé de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T. · 2010

Read Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. by Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabé de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2978704.txt.

Introduction

Suhre and colleagues ran a multi-platform scan of small molecules in blood from a German population study in 2010, hunting the metabolic footprint of diabetes. No single instrument can read the whole set of body chemicals, so they combined three.

Fasting blood from forty people reporting diabetes and sixty controls yielded measurements of several hundred distinct molecules by magnetic resonance and mass methods. Known diabetes signs reappeared, including a sugar marker, a ketone body, and certain amino acids, and traces of diabetes drugs were detectable. The exercise shows combined platforms can sketch disease chemistry in everyday population samples.

Catalog record

CREATORSuhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabé de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE63 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2978704

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting By Karsten Suhre, Christa Meisinger, Angela Döring, Elisabeth Altmaier, Petra Belcredi, Christian Gieger, David Chang, Michael V Milburn, Walter E Gall, Klaus M Weinberger, Hans-Werner Mewes, Martin Hrabé de Angelis Published in: PLoS ONE DOI: 10.1371/journal.pone.0013953 ABSTRACT Abstract Background Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally all endogenous metabolites in a biological fluid. However, no single analytic technique covers the entire spectrum of the human metabolome. Here we present results from a multiplatform study, in which we investigate what kind of results can presently be obtained in the field of diabetes research when combining metabolomics data collected on a complementary set of analytical platforms in the framework of an epidemiological study. Methodology/Principal Findings 40 individuals with self-reported diabetes and 60 controls (male, over 54 years) were randomly selected from the participants of the population-based KORA (Cooperative Health Research in the Region of Augsburg) study, representing an extensively phenotyped sample of the general German population. Concentrations of over 420 unique small molecules were determined in overnight-fasting blood using three different techniques, covering nuclear magnetic resonance and tandem mass spectrometry. Known biomarkers of diabetes could be replicated by this multiple metabolomic platform approach, including sugar metabolites (1,5-anhydroglucoitol), ketone bodies (3-hydroxybutyrate), and branched chain amino acids. In some cases, diabetes-related medication can be detected (pioglitazone, salicylic acid). Conclusions/Significance Our study depicts the promising potential of metabolomics in diabetes research by identification of a series of known and also novel, deregulated metabolites that associate with diabetes. Key observations include perturbations of metabolic pathways linked to kidney dysfunction (3-indoxyl sulfate), lipid metabolism (glycerophospholipids, free fatty acids), and interaction with the gut microflora (bile acids). Our study suggests that metabolic markers hold the potential to detect diabetes-related complications already under sub-clinical conditions in the general population. INTRODUCTION Type 2 diabetes mellitus is a complex disease [1], which is characterized by abnormal hepatic glucose output, insulin resistance and impaired insulin production [2], [3]. It may be assumed that in individuals with type 2 diabetes many metabolic pathways are likely to be affected and presumably play a role in their overall metabolic dysfunction. Thus, the identification of new biomarkers and pathways can improve the characterization of pathophysiological alterations associated with the disease condition [4]. Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally all endogenous metabolites in a biological fluid [5], [6], [7], [8], [9], [10]. Changes in metabolic profiles are a potential source of such biomarkers [11], [12], [13], [14]. We have previously reported an analysis of targeted quantitative metabolomics, where we have shown that many known and novel observations of metabolic changes may be discovered using such a metabolomics approach and that targeted quantitative metabolomics provides a functional readout of the metabolic state of diabetic mice under medication [15]. The method has the power to identify perturbations of the body's metabolic homeostasis and thereby offers access to markers of metabolic pathways that are impacted by the disease and/or medication. Such markers could help physicians to identify patients at high risk for specific complications, thereby allowing a personalized approach to monitoring and preventing progression to costly co-morbidities. The principal concept of metabolomics being able to find some metabolites differing in a control and a type 2 diabetic group is established. It is not our goal here to show this once again. The questions we ask are rather “How well are different approaches suited to attain this goal?” and “What are optimal settings under which such studies can be successful?”. Others have already investigated these questions before [16], [17], [18]. However, we believe that this topic is much too complex than to be answered fully in a single study. For instance, the work described in the recent paper in this journal by Lanza et al. [19] covers only a small patient group of 7 cases and 7 controls. Our study, in contrast is based on 40 cases and 60 controls from an epidemiological cohort. Work reviewed recently by Madsen et al. [20] overlaps to some extent with our study, but none of them address aspects related to sub-clinical signals in a general population. Our focus is on participants from epidemiological studies rather than on patients under clinical conditions. Herein, we identify a series of differentially “expressed” metabolites that associate with diabetes under sub-clinical conditions in the general population. This question has not been addressed to this extent by any published paper. In particular, we see our work as a pilot that bears the potential of being scaled up to much larger sample sizes, since population studies such as KORA eventually provide access to much larger sample sizes, taken under rigorous standardized blood sample collection conditions in dedicated study centers (e.g. overnight fasting, standard protocol for serum and plasma preparation, storage in liquid nitrogen until measurement). These kinds of samples generally have not been available from clinical studies until recently. It is in this light that we provide here a proof of concept that metabolomics can uncover key metabolites differing in a control and a type 2 diabetic group. Obtaining the most comprehensive coverage of the metabolome experimentally is key to identifying novel markers of diabetes using the metabolomics approach [4], [21], [22]. Over the past two years we have conducted experiments with three different fee-for-service providers of quantitative metabolomics: Biocrates Life Sciences AG (Austria), Chenomx Inc. (Canada), and Metabolon Inc. (USA) by submitting to each of them blood samples from the same 100 participants of the population-based study KORA (Cooperative Health Research in the Region of Augsburg) for metabolic characterization. The methods and the metabolic profiling platforms of the three companies are mostly complementary, but also provide some overlap which allows for a certain level of cross-validation. Biocrates and Metabolon apply tandem mass spectrometry (MS), whereas Chenomx specializes in nuclear magnetic resonance (NMR) spectroscopy. Furthermore, Metabolon takes a non-targeted approach, combining gas (GC) and liquid phase (LC) chromatography; whereas, Biocrates applies targeted metabolomics, based on pre-selected MRM pairs and isotope labeled internal standards, with many of their methods being based on rapid direct flow injection (FIA), however with capacity to carry out multiple GC-MS and LC-MS protocols. NMR has the advantage of leaving the sample intact, but requires much larger (10-100x) sample volumes. FIA-MS is especially adapted to high-throughput assays when large populations or time-series with many data points are investigated. One example is newborn screening for inborn errors of metabolism [23] where the power of metabolomics has been shown for the early detection of many monogenic disorders [24]. A combination of LC-MS and GC-MS assures a maximum coverage of a wide metabolite spectrum, but is more likely adapted to applications for metabolite biomarker discovery studies [25]. The metabolic approaches used here are thus technologically distinct but overlapping in targets identified. Here we present the results from these studies, which implement a case/control design in males aged over 55 years with type 2 diabetes. Because no single analytic technique covers the entire spectrum of the human metabolome, we ask what kind of results can presently be obtained in the field of diabetes research when combining metabolomics data collected on a complementary set of platforms in the context of

Read the complete text